{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:29:12Z","timestamp":1719448152642},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,26]]},"DOI":"10.7759\/cureus.63203","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T14:45:54Z","timestamp":1719413154000},"source":"Crossref","is-referenced-by-count":0,"title":["Alternative Dosing of Eltrombopag for the Treatment of Chronic, Steroid-Refractory Immune Thrombocytopenia"],"prefix":"10.7759","author":[{"given":"Salman","family":"Syed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadassah","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Ganz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garry","family":"Lachhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harinder","family":"Sawhney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra010501","article-title":"Immune thrombocytopenic purpura","volume":"346","author":"Cines DB","year":"2002","unstructured":"Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002, 346:995-1008. 10.1056\/NEJMra010501","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008287","article-title":"Eltrombopag in patients with chronic immune thrombocytopenia in Asia-Pacific, the Middle East, and Turkey: final analysis of CITE","volume":"7","author":"Wong RS","year":"2023","unstructured":"Wong RS, Yava\u015fo\u011flu \u0130, Yassin MA, et al.. Eltrombopag in patients with chronic immune thrombocytopenia in Asia-Pacific, the Middle East, and Turkey: final analysis of CITE. Blood Adv. 2023, 7:4773-81. 10.1182\/bloodadvances.2022008287","journal-title":"Blood Adv"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13717","article-title":"An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia","volume":"84","author":"Al-Samkari H","year":"2018","unstructured":"Al-Samkari H, Kuter DJ. An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia. Br J Clin Pharmacol. 2018, 84:2673-7. 10.1111\/bcp.13717","journal-title":"Br J Clin Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12260","article-title":"Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy","volume":"161","author":"Kuter DJ","year":"2013","unstructured":"Kuter DJ, Bussel JB, Newland A, et al.. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol. 2013, 161:411-23. 10.1111\/bjh.12260","journal-title":"Br J Haematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin receptor agonists: ten years later","volume":"104","author":"Ghanima W","year":"2019","unstructured":"Ghanima W, Cooper N, Rodeghiero F, Godeau B, Bussel JB. Thrombopoietin receptor agonists: ten years later. Haematologica. 2019, 104:1112-23. 10.3324\/haematol.2018.212845","journal-title":"Haematologica"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-425512","article-title":"Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study","volume":"121","author":"Saleh MN","year":"2013","unstructured":"Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013, 121:537-45. 10.1182\/blood-2012-04-425512","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa073275","article-title":"Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura","volume":"357","author":"Bussel JB","year":"2007","unstructured":"Bussel JB, Cheng G, Saleh MN, et al.. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007, 357:2237-47. 10.1056\/NEJMoa073275","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2011.05975.x","article-title":"The development of romiplostim for patients with immune thrombocytopenia (ITP)","volume":"86","author":"Molineux G","year":"2007","unstructured":"Molineux G. The development of romiplostim for patients with immune thrombocytopenia (ITP). Ann Hematol. 2007, 86:621-7. 10.1111\/j.1749-6632.2011.05975.x","journal-title":"Ann Hematol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.5045\/br.2015.50.1.19","article-title":"Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia","volume":"50","author":"Kim YK","year":"2015","unstructured":"Kim YK, Lee SS, Jeong SH, Ahn JS, Yang DH, Lee JJ, Kim HJ. Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia. Blood Res. 2015, 50:19-25. 10.5045\/br.2015.50.1.19","journal-title":"Blood Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-013-1382-0","article-title":"The biology of thrombopoietin and thrombopoietin receptor agonists","volume":"98","author":"Kuter DJ","year":"2013","unstructured":"Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013, 98:10-23. 10.1007\/s12185-013-1382-0","journal-title":"Int J Hematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61107-2","article-title":"Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomized, multicentre, placebo-controlled trial","volume":"386","author":"Grainger JD","year":"2015","unstructured":"Grainger JD, Locatelli F, Chotsampancharoen T, et al.. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomized, multicentre, placebo-controlled trial. Lancet. 2015, 386:1649-58. 10.1016\/S0140-6736(15)61107-2","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225565","article-title":"International consensus report on the investigation and management of primary immune thrombocytopenia","volume":"115","author":"Provan D","year":"2010","unstructured":"Provan D, Stasi R, Newland AC, et al.. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010, 115:168-86. 10.1182\/blood-2009-06-225565","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/236713-alternative-dosing-of-eltrombopag-for-the-treatment-of-chronic-steroid-refractory-immune-thrombocytopenia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T14:45:57Z","timestamp":1719413157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/236713-alternative-dosing-of-eltrombopag-for-the-treatment-of-chronic-steroid-refractory-immune-thrombocytopenia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.63203","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,26]]}}}